All In Biotech

Drug Trial Radar · NCT00216398

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR

Last checked: Nov 20, 2026Latest source record: Aug 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jun 2004

Primary completion

Jun 22, 2006

Study completion Jun 22, 2006

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.

Conditions

  • Acromegaly

Interventions

  • Lanreotide (Autogel formulation)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of patients with GH control (<5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Westmead Hospital

    Westmead, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.